Cabazitaxel injection
Products billed under this code include Jevtana.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Jevtana.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Jevtana | Sanofi-Aventis U.S. LLC | 00024-5824-11 | 60 | $13,901.28 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $231.688 | −$2.042 | 1 MG | Cabazitaxel injection | v1, posted September 17, 2026 |
| 3Q26 | $233.73 | +$2.682 | 1 MG | Cabazitaxel injection | v1, posted September 15, 2026 |
| 2Q26 | $231.048 | +$0.252 | 1 MG | Cabazitaxel injection | v1, posted September 15, 2026 |
| 1Q26 | $230.796 | +$3.519 | 1 MG | Cabazitaxel injection | v1, posted September 15, 2026 |
| 4Q25 | $227.277 | +$0.177 | 1 MG | Cabazitaxel injection | v1, posted September 8, 2026 |
| 3Q25 | $227.10 | +$5.395 | 1 MG | Cabazitaxel injection | v1, posted March 10, 2026 |
| 2Q25 | $221.705 | −$2.385 | 1 MG | Cabazitaxel injection | v1, posted March 10, 2026 |
| 1Q25 | $224.09 | +$7.635 | 1 MG | Cabazitaxel injection | v1, posted December 19, 2025 |
| 4Q24 | $216.455 | +$0.954 | 1 MG | Cabazitaxel injection | v1, posted June 11, 2025 |
| 3Q24 | $215.501 | +$3.746 | 1 MG | Cabazitaxel injection | v1, posted June 11, 2025 |
| 2Q24 | $211.755 | +$1.302 | 1 MG | Cabazitaxel injection | v1, posted March 11, 2025 |
| 1Q24 | $210.453 | +$1.113 | 1 MG | Cabazitaxel injection | v1, posted December 19, 2024 |
| 4Q23 | $209.34 | +$3.308 | 1 MG | Cabazitaxel injection | v1, posted October 10, 2024 |
| 3Q23 | $206.032 | +$6.448 | 1 MG | Cabazitaxel injection | v1, posted June 5, 2024 |
| 2Q23 | $199.584 | +$0.375 | 1 MG | Cabazitaxel injection | v1, posted February 23, 2024 |
| 1Q23 | $199.209 | +$3.556 | 1 MG | Cabazitaxel injection | v1, posted December 6, 2023 |
| 4Q22 | $195.653 | −$0.953 | 1 MG | Cabazitaxel injection | v1, posted June 22, 2023 |
| 3Q22 | $196.606 | +$5.658 | 1 MG | Cabazitaxel injection | v1, posted June 9, 2023 |
| 2Q22 | $190.948 | −$0.363 | 1 MG | Cabazitaxel injection | v1, posted December 14, 2022 |
| 1Q22 | $191.311 | +$2.314 | 1 MG | Cabazitaxel injection | v1, posted June 8, 2022 |
| 4Q21 | $188.997 | −$1.225 | 1 MG | Cabazitaxel injection | v1, posted June 2, 2022 |
| 3Q21 | $190.222 | +$6.16 | 1 MG | Cabazitaxel injection | v1, posted June 2, 2022 |
| 2Q21 | $184.062 | −$0.784 | 1 MG | Cabazitaxel injection | v1, posted March 1, 2022 |
| 1Q21 | $184.846 | – | 1 MG | Cabazitaxel injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.